Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Migration, Crosslink

📖

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-semaphorin-plexin-sign

📖 Wiki Page

therapeutic1266 wordssynced 2026-04-02

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Overview

flowchart TD Semaphorin_Plexin_Signaling_Mo["Semaphorin/Plexin Signaling Modulators for Neuro"] Semaphorin_Plexin_Signaling_Mo["table"] Semaphorin_Plexin_Signaling_Mo -->|"related to"| Semaphorin_Plexin_Signaling_Mo style Semaphorin_Plexin_Signaling_Mo fill:#81c784,stroke:#333,color:#000 Semaphorin_Plexin_Signaling_Mo["class"] Semaphorin_Plexin_Signaling_Mo -->|"related to"| Semaphorin_Plexin_Signaling_Mo style Semaphorin_Plexin_Signaling_Mo fill:#81c784,stroke:#333,color:#000 Semaphorin_Plexin_Signaling_Mo["infobox"] Semaphorin_Plexin_Signaling_Mo -->|"related to"| Semaphorin_Plexin_Signaling_Mo style Semaphorin_Plexin_Signaling_Mo fill:#81c784,stroke:#333,color:#000 style Semaphorin_Plexin_Signaling_Mo fill:#4fc3f7,stroke:#333,color:#000

...

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Semaphorin/Plexin Signaling Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">Anti-Sema3A mAb</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">VX-803 (Pepinemab)</td>
<td>Vaccinex</td>
</tr>
<tr>
<td class="label">Humanized anti-Sema3A</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Type</td>
</tr>
<tr>
<td class="label">NRP1-blocking peptides</td>
<td>Peptide</td>
</tr>
<tr>
<td class="label">Small molecule NRP1 antagonists</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">NRP1-Fc decoy receptor</td>
<td>Fusion protein</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">ROCK inhibitors</td>
<td>Fasudil, Y-27632</td>
</tr>
<tr>
<td class="label">Rac1 activators</td>
<td>NSC23766 derivatives</td>
</tr>
<tr>
<td class="label">RhoA inhibitors</td>
<td>C3 transferase</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV-sema3A shRNA</td>
<td>Sema3A</td>
</tr>
<tr>
<td class="label">AAV-dominant-negative Plexin-A</td>
<td>Plexin-A signaling</td>
</tr>
<tr>
<td class="label">CRISPR activation of NRP2</td>
<td>NRP2</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Anti-Sema3A + BDNF</td>
<td>Promote regeneration while providing trophic support</td>
</tr>
<tr>
<td class="label">Plexin modulator + anti-inflammatory</td>
<td>Combined effects on neuroinflammation</td>
</tr>
<tr>
<td class="label">NRP1 antagonist + LRRK2 inhibitor (PD)</td>
<td>Multi-target approach</td>
</tr>
<tr>
<td class="label">RhoGTPase mod + GSK-3beta inhibitor (AD)</td>
<td>Address multiple downstream pathways</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT05261208</td>
<td>Pepinemab (VX-803)</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Source</td>
</tr>
<tr>
<td class="label">Sema3A</td>
<td>CSF, plasma</td>
</tr>
<tr>
<td class="label">NRP1</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Plexin-A expression</td>
<td>PET (development)</td>
</tr>
<tr>
<td class="label">Synaptic density</td>
<td>PET (synaptic vesicle 2A)</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">APP/PS1 AD mice</td>
<td>Anti-Sema3A Ab</td>
</tr>
<tr>
<td class="label">5xFAD mice</td>
<td>NRP1 antagonist</td>
</tr>
<tr>
<td class="label">MPTP PD mice</td>
<td>Sema3A siRNA</td>
</tr>
<tr>
<td class="label">SOD1 ALS mice</td>
<td>Anti-Sema3A Ab</td>
</tr>
<tr>
<td class="label">Aged rats</td>
<td>Sema3A neutralization</td>
</tr>
</table>

Semaphorin/Plexin/Neuropilin signaling represents a promising cross-disease therapeutic target for neurodegenerative disorders. Originally characterized as axon guidance molecules during development, semaphorins play critical roles in adult synaptic plasticity, neuronal repair, neuroinflammation, and oligodendrocyte function. Dysregulated semaphorin signaling contributes to synaptic loss, impaired axonal regeneration, and neuroinflammation across multiple neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), CBS/PSP, frontotemporal dementia (FTD), and Huntington's disease (HD).

This therapeutic page covers pharmacological strategies to modulate semaphorin/plexin signaling for neuroprotection and regeneration.

Therapeutic Rationale

Why Target Semaphorin/Plexin Signaling?

Cross-disease relevance: Semaphorin dysregulation occurs in multiple neurodegenerative conditions, enabling platform therapeutic approaches.

Synaptic protection: Sema3A elevation in AD directly contributes to synaptic loss and dendritic spine elimination—core pathological features.

Regeneration promotion: Semaphorins are potent axonal repellents; blocking this signaling can enable compensatory axonal sprouting and regeneration.

Neuroinflammation modulation: Plexin-B signaling on microglia and astrocytes regulates inflammatory responses.

Multiple mechanistic pathways: Downstream effectors (Rho GTPases, PI3K/Akt, MAPK/ERK) offer multiple intervention points.

Disease-Specific Rationale

Alzheimer's Disease

Aβ oligomers upregulate Sema3A expression in neurons and astrocytes
Elevated Sema3A impairs dendritic spine formation and LTP
Sema3A signaling interferes with compensatory axonal sprouting
Tau pathology intersects with semaphorin signaling through GSK-3β modulation

Parkinson's Disease

Semaphorins guide dopaminergic neuron development and maintenance
Sema3A repulsion impairs axonal regeneration in the nigrostriatal pathway
Plexin-B signaling on microglia contributes to neuroinflammation
α-Synuclein aggregation affects semaphorin expression patterns

Amyotrophic Lateral Sclerosis

Elevated Sema3A in ALS models and patient tissue
Accelerated motor neuron death through excessive repulsion
Impaired regeneration at the neuromuscular junction
Oligodendrocyte dysfunction through Plexin-B signaling

CBS/PSP (4R Tauopathies)

Tau pathology affects axonal guidance molecule expression
Sema3A dysregulation contributes to network dysfunction
Axonal transport defects intersect with semaphorin signaling

FTD/HD

Network dysfunction involves semaphorin-mediated connectivity changes
Sema3A elevation contributes to synaptic disconnection

Therapeutic Strategies

1. Semaphorin Neutralization

Anti-Sema3A Antibodies

Mechanism: Neutralizing antibodies bind secreted Sema3A, preventing interaction with Neuropilin-1/Plexin-A receptors. This converts repulsive signals to permissive or attractive, promoting dendritic spine formation and axonal regeneration.

Preclinical evidence:

Anti-Sema3A antibodies restore dendritic spine density in AD mouse models
Promote axonal regeneration in aged brain and injury models
Improve LTP in hippocampal slices exposed to Aβ oligomers
Rescue motor neuron survival in ALS models

2. Receptor Antagonism

Neuropilin-1 Antagonists

NRP1 is the primary co-receptor for class 3 semaphorins. Blocking NRP1 prevents Sema3A and Sema3F signaling.

Plexin-A Modulators

Plexin-A1 antagonists: Block downstream repulsive signaling
Dominant-negative Plexin-A constructs: Compete with wild-type receptors

3. Downstream Pathway Targeting

Rho GTPase Modulators

Since Rho GTPases mediate semaphorin's cytoskeletal effects:

PI3K/Akt Pathway Modulators

Sema3A signaling affects PI3K/Akt, which intersects with cell survival pathways:

Akt activators: Support neuroprotection
GSK-3β inhibitors: Address Sema3A-tau intersection

4. cAMP Modulation

Raising intracellular cAMP levels can convert semaphorin responses from repulsive to attractive:

PDE inhibitors: Increase cAMP, modify semaphorin response
cAMP analogs: Direct activation

5. Gene Therapy Approaches

6. Combination Strategies

Clinical Development Pipeline

Active Clinical Trials

Preclinical Programs

Anti-Sema3A antibodies: Multiple academic groups and pharma companies developing candidates

Small molecule NRP1 antagonists: Lead optimization

Plexin-A modulators: Early discovery

Gene therapy vectors: AAV-mediated knock-down approaches

Disease-Specific Applications

Alzheimer's Disease

Therapeutic approach: Anti-Sema3A antibodies or NRP1 antagonists

Target patient population: Early to moderate AD (amyloid-positive, MCI)

Endpoints in development:

CSF Sema3A levels as pharmacodynamic marker
Synaptic density (PET)
Cognitive measures

Combination potential: With amyloid-targeting therapies (anti-Aβ antibodies, BACE inhibitors), neurotrophic factors

Parkinson's Disease

Therapeutic approach: Sema3A neutralization + Plexin-B modulation

Target patient population: Early PD, particularly with GBA or LRRK2 mutations

Rationale: Promote dopaminergic axon regeneration in the nigrostriatal pathway

Combination potential: With LRRK2 inhibitors, GBA modulators, GDNF

Amyotrophic Lateral Sclerosis

Therapeutic approach: Anti-Sema3A antibodies

Target patient population: SOD1, C9orf72, and sporadic ALS

Rationale: Address elevated Sema3A and promote motor neuron regeneration

Challenges: BBB penetration to spinal cord, timing of intervention

CBS/PSP

Therapeutic approach: Sema3A modulation

Target patient population: Probable CBS or PSP

Rationale: Address tau-related network dysfunction and axonal pathology

Biomarkers for Patient Selection

Challenges and Limitations

BBB penetration: Large molecule antibodies face challenges reaching CNS; engineering or blood-brain barrier modulation required.

Complexity of signaling: Semaphorin/plexin signaling is context-dependent; global blockade may have unintended effects.

Timing of intervention: Optimal timing relative to disease progression unclear.

Biomarker development: Patient selection biomarkers needed.

Off-target effects: Semaphorins have functions in immune system and other tissues.

Redundancy: Multiple semaphorins and receptors may provide compensatory pathways.

Preclinical Evidence Summary

[Semaphorin/Plexin Signaling Pathway in Neurodegeneration](/mechanisms/semaphorin-plexin-signaling-neurodegeneration)
[Sema3A Protein](/proteins/sema3a-protein)
[Plexin-A2 Protein](/proteins/plxna2-protein)
[Neuropilin-1 Protein](/proteins/nrp1-protein)
[Axon Guidance in Neurodegeneration](/mechanisms/axon-guidance-neurodegeneration)
[Synaptic Plasticity and Network Repair](/therapeutics/section-146-advanced-synaptic-plasticity-network-repair-cbs-psp)
[Tau Reduction Therapies](/therapeutics/tau-reduction-therapies)
[Neurotrophin Growth Factor Therapy](/therapeutics/section-141-advanced-neurotrophin-growth-factor-therapy-cbs-psp)

Last updated: 2026-03-28

References

[Kolodkin et al., Semaphorin family in nervous system development (2003)](https://pubmed.ncbi.nlm.nih.gov/14598225/)

[Fujisawa et al., Plexin structure and function (2004)](https://pubmed.ncbi.nlm.nih.gov/14722617/)

[Jian et al., Amyloid-beta upregulates Sema3A expression (2016)](https://pubmed.ncbi.nlm.nih.gov/27176468/)

[Xu et al., Semaphorins in Parkinson's disease models (2016)](https://pubmed.ncbi.nlm.nih.gov/26826330/)

[Kuzuya et al., Semaphorin in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31793923/)

[Cheng et al., Plexin-B signaling in neuroinflammation (2014)](https://pubmed.ncbi.nlm.nih.gov/25539893/)

[Santos et al., Semaphorin3A and PI3K/Akt in neuroprotection (2012)](https://pubmed.ncbi.nlm.nih.gov/22466793/)

[Vaccinex Inc., VX-803 in Alzheimer's disease (2024)](https://clinicaltrials.gov/)

[Gabeur et al., Neuropilin-1 as therapeutic target (2022)](https://pubmed.ncbi.nlm.nih.gov/35545467/)

[Liu et al., PlexinA2 modulates synaptic function in AD (2025)](https://pubmed.ncbi.nlm.nih.gov/38493125/)

[Chen et al., Sema3A neutralization promotes axonal regeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38762341/)

[Matsumoto et al., Sema3A elevation in ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/31176184/)

📖 View canonical wiki page →

Related Entities

therapeutics-semaphorin-plexin-signaling-modulators

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-semaphorin-plexin-signaling-modulators
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d96cb07bacc5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-semaphorin-plexin-signaling-modulators'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

544

Outgoing

697

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Overview

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Overview

Therapeutic Rationale

Why Target Semaphorin/Plexin Signaling?

Disease-Specific Rationale

Therapeutic Strategies

1. Semaphorin Neutralization

2. Receptor Antagonism

3. Downstream Pathway Targeting

4. cAMP Modulation

5. Gene Therapy Approaches

6. Combination Strategies

Clinical Development Pipeline

Active Clinical Trials

Preclinical Programs

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

CBS/PSP

Biomarkers for Patient Selection

Challenges and Limitations

Preclinical Evidence Summary

References

💬 Discussion

📗 Cite This Artifact

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Overview

Semaphorin/Plexin Signaling Modulators for Neurodegeneration

Overview

Therapeutic Rationale

Why Target Semaphorin/Plexin Signaling?

Disease-Specific Rationale

Therapeutic Strategies

1. Semaphorin Neutralization

2. Receptor Antagonism

3. Downstream Pathway Targeting

4. cAMP Modulation

5. Gene Therapy Approaches

6. Combination Strategies

Clinical Development Pipeline

Active Clinical Trials

Preclinical Programs

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

CBS/PSP

Biomarkers for Patient Selection

Challenges and Limitations

Preclinical Evidence Summary

Related Pages

References

💬 Discussion